|
Business Combination - Additional Information (Detail) (USD $)
|
12 Months Ended |
0 Months Ended |
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2014
CommercialTests
|
Jun. 10, 2014
|
| Business Acquisition [Line Items] |
|
|
|
|
|
| Goodwill acquired in business combination, estimated fair value |
$ 12,005,000us-gaap_Goodwill |
$ 0us-gaap_Goodwill |
|
12,005,000us-gaap_Goodwill |
|
| Stock-based compensation |
535,000us-gaap_ShareBasedCompensation |
72,000us-gaap_ShareBasedCompensation |
69,000us-gaap_ShareBasedCompensation |
|
|
| ImmuMetrix, Inc. [Member] |
|
|
|
|
|
| Business Acquisition [Line Items] |
|
|
|
|
|
| Acquisition date |
Jun. 10, 2014 |
|
|
|
|
| Estimated purchase price |
|
|
|
|
17,200,000us-gaap_BusinessCombinationConsiderationTransferred1 / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember |
| Business acquisition purchase price, cash |
|
|
|
|
600,000cdna_BusinessAcquisitionCashConsideration / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember |
| Milestone description |
The milestone will be achieved if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States no later than six years after the closing date of the acquisition. |
|
|
|
|
| Number of commercial tests involving the measurement of cfDNA to be completed |
2,500cdna_NumberOfCommercialTests / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember |
|
|
2,500cdna_NumberOfCommercialTests / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember |
|
| Milestone measurement period |
6 years |
|
|
|
|
| Goodwill acquired in business combination, estimated fair value |
|
|
|
|
12,000,000us-gaap_Goodwill / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember |
| Estimated remaining useful life of patent |
15 years |
|
|
|
|
| Business combination pro forma removal (addition) in income tax benefit |
1,500,000cdna_BusinessAcquisitionsProFormaAdjustmentIncreaseDecreaseInIncomeTaxExpenseBenefit / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember |
1,500,000cdna_BusinessAcquisitionsProFormaAdjustmentIncreaseDecreaseInIncomeTaxExpenseBenefit / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember |
|
|
|
| ImmuMetrix, Inc. [Member] | CareDx, Inc [Member] |
|
|
|
|
|
| Business Acquisition [Line Items] |
|
|
|
|
|
| Acquisition-related costs |
1,700,000cdna_BusinessAcquisitionCostOfAcquiredEntityTransactionCostsExpensedDuringPeriod / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember / dei_LegalEntityAxis = us-gaap_ParentCompanyMember |
|
|
|
|
| Stock-based compensation |
200,000us-gaap_ShareBasedCompensation / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember / dei_LegalEntityAxis = us-gaap_ParentCompanyMember |
|
|
|
|
| ImmuMetrix, Inc. [Member] | Contingent consideration [Member] |
|
|
|
|
|
| Business Acquisition [Line Items] |
|
|
|
|
|
| Shares issued, shares issuable upon achievement of future milestone, and options assumed |
|
|
|
227,845us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember / us-gaap_ContingentConsiderationByTypeAxis = cdna_ContingentPaymentMember |
|
| Milestone description |
The issuance will occur if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States by June 10, 2020. |
|
|
|
|
| ImmuMetrix, Inc. [Member] | In-process technology [Member] |
|
|
|
|
|
| Business Acquisition [Line Items] |
|
|
|
|
|
| Assets acquired in business combination, estimated fair value |
|
|
|
|
6,700,000us-gaap_FinitelivedIntangibleAssetsAcquired1 / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_InProcessResearchAndDevelopmentMember |
| Accumulated amortization of intangible asset |
0us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_InProcessResearchAndDevelopmentMember |
|
|
0us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_InProcessResearchAndDevelopmentMember |
|
| ImmuMetrix, Inc. [Member] | Series G Preferred Stock [Member] |
|
|
|
|
|
| Business Acquisition [Line Items] |
|
|
|
|
|
| Shares issued, shares issuable upon achievement of future milestone, and options assumed |
|
|
|
|
911,364us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember / us-gaap_StatementClassOfStockAxis = us-gaap_SeriesGPreferredStockMember |
| Estimated fair value |
|
|
|
|
14,200,000us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember / us-gaap_StatementClassOfStockAxis = us-gaap_SeriesGPreferredStockMember |
| ImmuMetrix, Inc. [Member] | Series G Preferred Stock [Member] | Contingent consideration [Member] |
|
|
|
|
|
| Business Acquisition [Line Items] |
|
|
|
|
|
| Shares issued, shares issuable upon achievement of future milestone, and options assumed |
|
|
|
|
227,845us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember / us-gaap_ContingentConsiderationByTypeAxis = cdna_ContingentPaymentMember / us-gaap_StatementClassOfStockAxis = us-gaap_SeriesGPreferredStockMember |
| Estimated fair value |
|
|
|
1,100,000us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember / us-gaap_ContingentConsiderationByTypeAxis = cdna_ContingentPaymentMember / us-gaap_StatementClassOfStockAxis = us-gaap_SeriesGPreferredStockMember |
2,300,000us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember / us-gaap_ContingentConsiderationByTypeAxis = cdna_ContingentPaymentMember / us-gaap_StatementClassOfStockAxis = us-gaap_SeriesGPreferredStockMember |
| ImmuMetrix, Inc. [Member] | Series G Preferred Stock [Member] | Stock Options [Member] |
|
|
|
|
|
| Business Acquisition [Line Items] |
|
|
|
|
|
| Shares issued, shares issuable upon achievement of future milestone, and options assumed |
|
|
|
|
23,229us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember / us-gaap_OptionIndexedToIssuersEquityTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_StatementClassOfStockAxis = us-gaap_SeriesGPreferredStockMember |
| Estimated fair value |
|
|
|
|
$ 369,000us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable / us-gaap_BusinessAcquisitionAxis = cdna_ImmumetrixIncMember / us-gaap_OptionIndexedToIssuersEquityTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_StatementClassOfStockAxis = us-gaap_SeriesGPreferredStockMember |